Tissue Plasminogen Activator
<p>Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion</p>
... Purpose: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macula[r] ...
10
High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study
... of tissue plasminogen activator (tPA) or high activity of its inhibitor (PAI-1), as independent risk factors for CVD is unclear, as these variables seem to mirror most compo- nents of the insulin ...
7
Structural and kinetic comparison of recombinant human single and two chain tissue plasminogen activator
... single-chain tissue plasminogen activator (sct-PA) and two-chain tissue plasminogen activator (tct-PA), and compared these structural data with measurement of enzymatic ...
8
Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
... Keywords: tissue plasminogen activator (rTPA), vitreous body, macular hole, vitrectomy, epiretinal membrane, diabetic retinopathy.. Introduction.[r] ...
10
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
... PAI-1: plasminogen activator inhibitor-1; SBP: systolic blood pressure; TG: triglycerides; tPA: tissue plasminogen activator; T2D: type 2 diabetes; UMMC: University Malaya medical ...
9
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers.
... intravenous tissue plasminogen activator (IV tPA) administration before endovascular intervention as compared to without at thrombectomy‑capable low‑volume centers on procedural aspects and patient ...
5
Tissue plasminogen activator promotes platelet disaggregation in plasma
... We studied the disaggregation of human platelets by tissue-type plasminogen activator (t- PA). When added to a suspension of human platelets induced to aggregate in plasma with adenosine ...
8
The regulation of tissue plasminogen activator in rat brain glioma cells
... T h ese studies on the reg u latio n of genes in the fib rin o ly tic sy stem p ro v id es an in sig h t in to c o o rd in a te re g u la tio n and expression of genes in a com plex system . A nother facto r that has an ...
212
Binding of tissue plasminogen activator to cultured human endothelial cells
... involving binding sites of both high (Kd, 28.7 +/- 10.8 pM; Bmax, 3,700 +/- 300) and low (Kd, 18.1 +/- 3.8 nM; Bmax 815,000 +/- 146,000) affinity. t-PA binding was 70% inhibited by a 100-fold molar excess of u-PA. When ...
9
Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
... lets compared with 5.02 ± 0.7 for control), which to- gether indicates stimulation of fibrinolysis by plate- lets. It should also be noted that in the presence of platelets, fibrin polymerization was accompanied by an ...
11
Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
... Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Pneumatic displacement of[r] ...
8
GLP-1 RECEPTOR ACTIVATION-BASED THERAPY; A PROMISING STRATEGY AGAINST ISCHEMIC STROKE
... recombinant tissue plasminogen activator (rtpa) treatment in animal models of ischemic stroke (28, 29), The correlation between hyperglycemia and aggravated cerebral injury in stroke yielding a poor ...
6
Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
... Results: Thirty seven patients with acute ischemic stroke who treated with recombinant tissue plasminogen activator (r-TPA) were studied. There were hemorrhagic transformations in 9 (24%) patients. ...
6
Central serous chorioretinopathy: a pathogenetic model
... Abstract: Despite numerous studies describing predominantly its demography and clinical course, many aspects of central serous chorioretinopathy (CSCR) remain unclear. Perhaps the major impediment to finding an effective ...
5
Role of t-PA and PAI-1 variants in temporal lobe epilepsy in Chinese Han population
... encoding tissue plasminogen activator ...plasma, plasminogen activator Table 2 Genotypic distribution of the t-PA and PAI-1 gene between TLE patients and ...
6
The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
... The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on ...
13
Management of Plastic Bronchitis With Topical Tissue-type Plasminogen Activator
... Four months later, the patient pre- sented with respiratory distress, fever, cough, and chest pain. He was admitted to our hospital, where his chest radio- graph again revealed opaci fi cation of the left hemithorax. He ...
7
Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase
... enhance plasminogen activator activity in the ...plasma activator, milk activator, and tissue activator from the adrenals are immunologically distinct from human ...
17
alpha Fucose mediated binding and degradation of tissue type plasminogen activator by HepG2 cells
... Binding and degradation of tissue-type plasminogen activator by the human hepatoma cell line HepG2.. Interactions between tissue-type plasminogen activator and extracellular matrix assoc[r] ...
9
Localization of the binding site of tissue type plasminogen activator to fibrin
... of tissue-type plasminogen ...two-chain tissue-type plasminogen activator, however, destroyed both the binding and catalytic ...of tissue-type plasminogen activator ...
8